2. Academic Validation
  3. Predictive modeling & mechanistic validation of synergistic pimodivir combinations for anti-influenza therapy via PB2cap affinity boost

Predictive modeling & mechanistic validation of synergistic pimodivir combinations for anti-influenza therapy via PB2cap affinity boost

  • NPJ Digit Med. 2025 Nov 21;8(1):712. doi: 10.1038/s41746-025-02083-2.
Peng Luo # 1,  Kexin Li # 1,  Yubin Xie # 1,  Kun Huang # 1,  Zhenzhi Qin 1,  Jian-Piao Cai 1,  Yu Fu 1,  Jianli Cao 1,  Sihang Cao 1,  Ziyao Zhou 2,  Zi-Wei Ye 3,  Shuofeng Yuan 4 5 6 7
Affiliations

Affiliations

  • 1 Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.
  • 2 College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, China.
  • 3 School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.
  • 4 Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China. [email protected].
  • 5 State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China. [email protected].
  • 6 Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Ma Liu Shui, Hong Kong Special Administrative Region, China. [email protected].
  • 7 Pandemic Research Alliance Unit at the University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China. [email protected].
  • # Contributed equally.
PMID: 41272280 DOI: 10.1038/s41746-025-02083-2
Abstract

This study introduces a machine learning framework to predict effective Antiviral combinations for influenza A. It identifies Pimodivir with Epinephrine or L-Adrenaline as synergistic agents, confirmed by experiments demonstrating increased binding affinity and viral suppression. Multiple synergy scoring methods validate these drug combinations' potential, offering a strategic pathway for designing rational combination therapies against influenza and Other RNA viruses.

Figures
Products